Health

STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 23/10/2026, 10:36:24 UTC.

Briefings

Clinical trial results from a 2026 study published by STAT+ report that the Tango regimen combined with Rasonque achieved an 82% tumor response rate in advanced pancreatic cancer patients. The regimen was notable for its lack of chemotherapy, with 88% of patients remaining tumor-free at nine months. This finding supports the theory that combination targeted therapies offer superior benefits over single-agent treatments for this aggressive cancer type.

Key points

• The Tango regimen combined with Rasonque achieved an 82% tumor response rate in patients with advanced pancreatic cancer.
• 88% of patients remained tumor-free at nine months without chemotherapy.

Context

STAT+ reported this finding on October 23, 2026, highlighting a potential shift in treatment paradigms for aggressive pancreatic cancer by prioritizing targeted combinations over traditional chemotherapy.

Limitations

Data is limited to nine-month follow-up assessments; long-term survival outcomes beyond this period are not reported.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 23/10/2026, 10:37:29 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeid7otwzbngqntt72ezxdhgwqshoqnlebj27m67jinnv7n5tihgzmu